Epigenetic inhibitor silences KRAS-driven oncogenes
vol.24 iss.10 (2025) pp.1 Gut microbiota–derived metabolite drives atherosclerosis
vol.24 iss.10 (2025) pp.1 FDA new drug approvals in Q2 2025
vol.24 iss.8 (2025) pp.1 A neonatal window for in vivo gene therapy in haematopoietic stem cells.
vol.24 iss.8 (2025) In utero ASO therapy for spinal muscular atrophy
vol.24 iss.7 (2025) pp.1 Top companies and drugs by sales in 2024
vol.24 iss.4 (2025) pp.1 Outlook for medicines development and use in 2025.
vol.24 iss.2 (2025) 2024 FDA approvals.
vol.24 iss.2 (2025) FDA approves next-generation triple therapy for cystic fibrosis.
vol.24 iss.2 (2025) DLL3 draws two antibody-drug conjugate deals.
vol.24 iss.2 (2025) 2024 FDA approvals exceed average number but have lower sales projections.
vol.24 iss.2 (2025) Biopharma dealmaking in 2024.
vol.24 iss.2 (2025) Engineered T cells traverse new terrain.
vol.24 iss.2 (2025) Pairing up with GLP-1 to combat obesity.
vol.24 iss.2 (2025) Lipid nanoparticle ferries therapeutic mRNA to the placenta.
vol.24 iss.2 (2025) Cough suppressant reverses lung scarring.
vol.24 iss.2 (2025) Harnessing the biology of regulatory T cells to treat disease.
vol.24 iss.2 (2025) Targeting lysine acetylation readers and writers.
vol.24 iss.2 (2025) Vaccines for cancer prevention: exploring opportunities and navigating challenges.
vol.24 iss.2 (2025) Antiviral target compound profile for pandemic preparedness.
vol.24 iss.2 (2025) The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships.
vol.24 iss.1 (2025) Na V 1.8 inhibitor poised to provide opioid-free pain relief.
vol.24 iss.1 (2025) FDA approves L-amino acid decarboxylase deficiency gene therapy.
vol.24 iss.1 (2025) FDA approves first menin inhibitor, for acute leukaemia.
vol.24 iss.1 (2025) Top product forecasts for 2025.
vol.24 iss.1 (2025) Upcoming FDA approval decisions in Q1 2025.
vol.24 iss.1 (2025) Can non-canonical amino acids open up non-canonical drug discovery opportunities?
vol.24 iss.1 (2025) Two decades of new drug approvals in Japan.
vol.24 iss.1 (2025) StitchR platform joins up gene therapy payloads.
vol.24 iss.1 (2025) NK2R agonist delivers one-two punch to obesity.
vol.24 iss.1 (2025) Covalent inhibitor engages oncogenic AKT kinase.
vol.24 iss.1 (2025) ENGases to treat IgG-mediated diseases.
vol.24 iss.1 (2025) DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications.
vol.24 iss.1 (2025) The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap.
vol.24 iss.1 (2025) Senescence as a therapeutic target in cancer and age-related diseases.
vol.24 iss.1 (2025) Author Correction: B cell depletion therapies in autoimmune disease: advances and mechanistic insights.
vol.24 iss.1 (2025) Clinical development success rates for durable cell and gene therapies.
(2025) Genetics opens new route to degrader discovery.
(2025) A platform for personalized ASO therapeutics.
(2025) Adrenomedullin triggers insulin resistance.
(2025) Reversing lysosomal dysfunction to treat PAH.
(2025) Oral STING agonist inhibits tumour growth.
(2025) Androgen membrane receptor modulates muscle strength.
(2025) MYC in cancer: from undruggable target to clinical trials.
(2025) Can large, simple trials bring drug developers back to common diseases?
(2025) First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon.
(2025) Approvals by the China NMPA in 2024.
(2025) A new European platform for advancing regulatory science research.
(2025) FDA approves TROP2-targeted antibody-drug conjugate for breast cancer.
(2025) Directing autophagy to degrade cell surface receptors.
(2025)
vol.24 iss.10 (2025) pp.1 Gut microbiota–derived metabolite drives atherosclerosis
vol.24 iss.10 (2025) pp.1 FDA new drug approvals in Q2 2025
vol.24 iss.8 (2025) pp.1 A neonatal window for in vivo gene therapy in haematopoietic stem cells.
vol.24 iss.8 (2025) In utero ASO therapy for spinal muscular atrophy
vol.24 iss.7 (2025) pp.1 Top companies and drugs by sales in 2024
vol.24 iss.4 (2025) pp.1 Outlook for medicines development and use in 2025.
vol.24 iss.2 (2025) 2024 FDA approvals.
vol.24 iss.2 (2025) FDA approves next-generation triple therapy for cystic fibrosis.
vol.24 iss.2 (2025) DLL3 draws two antibody-drug conjugate deals.
vol.24 iss.2 (2025) 2024 FDA approvals exceed average number but have lower sales projections.
vol.24 iss.2 (2025) Biopharma dealmaking in 2024.
vol.24 iss.2 (2025) Engineered T cells traverse new terrain.
vol.24 iss.2 (2025) Pairing up with GLP-1 to combat obesity.
vol.24 iss.2 (2025) Lipid nanoparticle ferries therapeutic mRNA to the placenta.
vol.24 iss.2 (2025) Cough suppressant reverses lung scarring.
vol.24 iss.2 (2025) Harnessing the biology of regulatory T cells to treat disease.
vol.24 iss.2 (2025) Targeting lysine acetylation readers and writers.
vol.24 iss.2 (2025) Vaccines for cancer prevention: exploring opportunities and navigating challenges.
vol.24 iss.2 (2025) Antiviral target compound profile for pandemic preparedness.
vol.24 iss.2 (2025) The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships.
vol.24 iss.1 (2025) Na V 1.8 inhibitor poised to provide opioid-free pain relief.
vol.24 iss.1 (2025) FDA approves L-amino acid decarboxylase deficiency gene therapy.
vol.24 iss.1 (2025) FDA approves first menin inhibitor, for acute leukaemia.
vol.24 iss.1 (2025) Top product forecasts for 2025.
vol.24 iss.1 (2025) Upcoming FDA approval decisions in Q1 2025.
vol.24 iss.1 (2025) Can non-canonical amino acids open up non-canonical drug discovery opportunities?
vol.24 iss.1 (2025) Two decades of new drug approvals in Japan.
vol.24 iss.1 (2025) StitchR platform joins up gene therapy payloads.
vol.24 iss.1 (2025) NK2R agonist delivers one-two punch to obesity.
vol.24 iss.1 (2025) Covalent inhibitor engages oncogenic AKT kinase.
vol.24 iss.1 (2025) ENGases to treat IgG-mediated diseases.
vol.24 iss.1 (2025) DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications.
vol.24 iss.1 (2025) The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap.
vol.24 iss.1 (2025) Senescence as a therapeutic target in cancer and age-related diseases.
vol.24 iss.1 (2025) Author Correction: B cell depletion therapies in autoimmune disease: advances and mechanistic insights.
vol.24 iss.1 (2025) Clinical development success rates for durable cell and gene therapies.
(2025) Genetics opens new route to degrader discovery.
(2025) A platform for personalized ASO therapeutics.
(2025) Adrenomedullin triggers insulin resistance.
(2025) Reversing lysosomal dysfunction to treat PAH.
(2025) Oral STING agonist inhibits tumour growth.
(2025) Androgen membrane receptor modulates muscle strength.
(2025) MYC in cancer: from undruggable target to clinical trials.
(2025) Can large, simple trials bring drug developers back to common diseases?
(2025) First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon.
(2025) Approvals by the China NMPA in 2024.
(2025) A new European platform for advancing regulatory science research.
(2025) FDA approves TROP2-targeted antibody-drug conjugate for breast cancer.
(2025) Directing autophagy to degrade cell surface receptors.
(2025)
